Citi analyst Samantha Semenkow initiated coverage of 9 Meters Biopharma with a Neutral rating and $2.70 price target. The company’s cash runway is only sufficient to support operations through Q1 of 2023 and management is currently exploring all options for financing, the analyst tells investors in a research note. Citi is on the sidelines ahead of assurance that additional capital has been secured. It finds it difficult to recommend a stock "that has such a short runway."
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly